Adenovirus Infection Alters Pharmacokinetics of Chemotherapeutic Agents

Researchers at The University of Texas at Austin have found that infection with recombinant adenoviruses can significantly alter the pharmacokinetics of chemotherapeutic agents, such as docetaxel, used in cancer treatment. This is concerning because it may cause variability in the efficacy and safety of these treatments. The study, published in Cancer Gene Therapy, suggests that adenovirus infection should be taken into account when designing therapeutic regimens for patients with viral infections.

Key Takeaways:

• Infection with recombinant adenoviruses can significantly alter the pharmacokinetics of chemotherapeutic agents, such as docetaxel.
• The study found that a single dose of recombinant adenovirus expressing beta-galactosidase (AdlacZ) significantly alters CYP3A2, the correlate of CYP3A4, in rats for 14 days.
• Recombinant adenovirus expressing human p53 (Adp53) also suppresses CYP3A2, leading to reduced plasma clearance of docetaxel.
• The study suggests that adenovirus infection may cause significant variability in the pharmacokinetics and pharmacodynamics of anti-cancer agents.
• The researchers conclude that adenovirus infection should be considered when designing therapeutic regimens for patients with viral infection and those enrolled in clinical trials using recombinant viruses.
• The study emphasizes the importance of considering viral infections when treating cancer patients with chemotherapeutic agents.

Statistics:

• A single dose of recombinant adenovirus (Ad) expressing beta-galactosidase (AdlacZ) significantly alters CYP3A2 in rats for 14 days.
• Plasma clearance of docetaxel (DTX) in animals given AdlacZ was significantly lower than that of those given DTX alone (3.38±0.22 l h(-1) kg(-1) vs. 7.35±1.22 l h(-1) kg(-1)).
• Recombinant adenovirus expressing human p53 (Adp53) suppressed CYP3A2, leading to reduced plasma clearance of docetaxel.

Sources:

• Wonganan, P., et al. (2009). Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Therapy, 16(5), 405-414.
• Nature Publishing Group. (2009). Cancer Gene Therapy. Journal available online through subscription.